Diagnostic and prognostic value of nucleolar proteins in the regulation of tumor cells proliferation in patients with lung carcinoma and adrenocortical cancer

Cover Page

Cite item


We studied correlation between the degree of malignancy, prognosis, survival of oncological patients, and the number of proliferating cells (Ki-67 index), the rate of cell proliferation, the continuance of the mitotic cycle (and the expression of Ag-OYAOR-proteins-В23/nucleofozimine S23/nukleoline) in 16 patients with adrenocortical carcinoma and in 20 cases of “small” lung cancer (up to 3 cm in diameter), whose tumors were removed and long-term results were evaluated. The comparative study of proliferative activity of cells in the two groups of patients with different survival period after tumor removal showed the heterogeneity of Ki-67 index, which determined the number of proliferating cells. In the first group of patients (with a good prognosis) Ki-67 index was high, and expression of Ag-OYAOR proteins was low. At the same time, in the second group of patients, whose prognosis was poor, Ki-67 index in the tumor was low, but the expression of Ag-OYAOR-protein was high. So, we can make a conclusion, that it is impossible to discuss the degree of malignancy of the tumor and the prognosis, based only on Ki-67 index. Ag-OYAOR-protein and Ki-67 index reflect different aspects of cell proliferation: the rate of cell proliferation (Ag-OYAOR expression) and the number of proliferating cells (Ki-67 index).

About the authors

N T Reikhlin

Russian Cancer Research Center n. a. N. Blokhin

I A Bukaeva

Russian Cancer Research Center n. a. N. Blokhin

E A Smirnova

Russian Cancer Research Center n. a. N. Blokhin

A V Filimonyuk

Peoples’ Friendship University of Russia

Email: rudnvestnik@yandex.ru
Department of general practice


Copyright (c) 2012 Райхлин Н.Т., Букаева И.А., Смирнова Е.А., Филимонюк А.В.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies